基于赋能理论模式的多维护理干预对卵巢癌化疗患者营养状况及心理状态的影响

分析基于赋能理论模式的多维护理干预对卵巢癌化疗患者营养状况及心理状态的影响。方法 选取68例卵巢癌化疗患者,时间为:2022年1月-2024年5月,分组依据为计算机随机法,对照组实施常规护理干预、观察组实施基于赋能理论模式的多维护理干预,对比两组患者营养指标、心理状态及睡眠质量。结果 护理后营养指标对比,分析得出观察组显著优于对照组(P<0.05);护理后心理状态对比,分析得出观察组显著优于对照组(P<0.05);护理后睡眠质量对比,分析得出观察组显著优于对照组(P<0.05)。结论 基于赋能理论模式的多维护理干预不仅显著改善了卵巢癌化疗患者的营养状况与心理状态,还进一步提升了患者的睡眠质量,值得推广。

舒适护理对卵巢癌化疗患者负性情绪的改善价值研究

目的探讨舒适护理对卵巢癌化疗患者负性情绪的改善价值。方法研究对象选自我院2015年3月-2016年3月收治的50例卵巢癌化疗患者,依据随机平均原则划分为参照组25例与研究组25例。参照组患者行常规护理干预,研究组患者行舒适护理模式。对两组患者的焦虑抑郁情绪以及护理意度情况进行记录与分析。结果研究组患者的焦虑与抑郁情绪评分明显低于参照组,差异有统计学意义(P<0.05);研究组患者的护理满意度显著高于参照组,差异有统计学意义(P<0.05)。结论舒适化的护理模式不仅能够降低患者的焦虑与抑郁评分同时还能提高患者的护理满意度,改善临床护理质量,值得临床推广与应用。

心理护理联合健康指导在晚期卵巢癌化疗患者中的应用效果

目的探讨心理护理及健康指导在晚期卵巢癌化疗患者中的应用效果。方法选取2015年3月~2017年1月我院收治的80例晚期卵巢癌化疗患者作为研究对象,随机将其分为两组,每组各40例。普通组患者进行常规护理干预,干预组患者在普通组基础上进行心理护理及健康指导。比较两组患者的晚期卵巢癌化疗效果、卵巢癌疾病知识认知情况、化疗依从性情况、护理满意度评分及干预前后患者SCL-90量表中各项心理状态相关指标。结果干预组患者的卵巢癌化疗总有效率(92.50%)高于普通组(75.00%),差异有统计学意义(P<0.05);干预组患者的卵巢癌疾病知识认知情况、化疗依从性情况、护理满意度评分均高于普通组,差异有统计学意义(P<0.05);干预前,两组患者的SCL-90量表各指标评分比较,差异无统计学意义(P>0.05);干预后,干预组患者的SCL-90量表各指标评分低于普通组,差异有统计学意义(P<0.05)。结论心理护理及健康指导在晚期卵巢癌化疗患者中的应用效果确切,可有效改善患者的负性情绪,使其加深对卵巢癌疾病知识认知,提高化疗依从性以及护理满意度,提高化疗效果,值得推广应用。

延续性护理对卵巢癌术后化疗患者的影响分析

目的探究对卵巢癌术后化疗患者实施延续性护理的影响。方法选取2021年1月—2023年1月赤峰市医院收治的70例卵巢癌术后化疗患者为研究对象,按照随机抽签法将患者分为观察组和对照组,每组35例。观察组采用延续性护理,对照组采用常规护理,比较两组自我效能感、患者护理满意度、并发症发生情况、生存质量、遵医行为等。结果护理后,观察组自我效能感评分、护理总满意率高于对照组,差异有统计学意义(P<0.05);观察组肠梗阻、肾积水、血栓发生率低于对照组,差异有统计学意义(P<0.05);观察组社会、环境、躯体、心理评分均高于对照组,差异有统计学意义(P<0.05);观察组遵医行为评分高于对照组,差异有统计学意义(P<0.05)。结论延续性护理用于卵巢癌术后化疗患者,可提升护理效果,同时改善临床生存质量指标,降低各项并发症的发生率,改善自我效能感,显著提升患者的遵医行为,值得临床应用。

综合护理对卵巢癌化疗患者的影响研究

研究综合护理对卵巢癌化疗患者的影响。方法:对2018年7月~2020年7月间的48例卵巢癌化疗患者进行对比研究,先按照治疗顺序进行平均分组,再给予对照组(n=24)患者常规护理、实验组(n=24)患者综合护理,化疗后以SF-36生活质量量表进行测评,统计患者化疗后出现的不良反应、观察患者依从行为及满意度,再予以差异分析。结果:实验组躯体疼痛、生理功能、心理健康及日常活力量表得分均显著高于对照组,p<0.05;实验组不良反应共2例(8.33%)明显优于对照组5例(20.83%),差异显著即p<0.05;实验组依从性91.67%(22/24)及满意度95.83%(23/24)均显著高于对照组,p<0.05。结论:综合护理在卵巢癌化疗患者中的应用效果明显好于常规护理,不仅可以提高患者化疗后的生活质量,同时还可以有效减少化疗后的不良反应,患者的依从性及满意度也相对更高,为此应当得到广泛应用。

正念减压疗法联合有氧运动对化疗期卵巢癌患者睡眠及生命质量的影响

目的:探讨正念减压疗法联合有氧运动对化疗期卵巢癌患者睡眠及生命质量的影响。方法:选取2017年2月至2018年11月福建医科大学附属第一医院收治的化疗期卵巢癌患者98例作为研究对象,按照随机数字表法分为对照组与观察组,每组49例。对照组进行正念减压疗法,观察组进行有氧运动,观察2组患者睡眠及生命质量的变化。结果:干预后,观察组患者的睡眠质量评分明显低于对照组,2组比较差异有统计学意义(P<0.05);干预后,2组患者的生命质量改善率分别为89.80%、67.35%,2组比较差异有统计学意义(P<0.05)。结论:正念减压疗法联合有氧运动对化疗期卵巢癌患者有显著效果,能够提高患者睡眠质量,改善患者生命质量,值得临床推广。

Metronomic chemotherapy as a palliative treatment in poor performance status patients with advanced epithelial ovarian carcinoma

Objective：The aim of our study was to evaluate the clinical efficacy and tolerability of metronomic chemotherapy in patients with advanced ovarian carcinoma.Methods：Fifteen patients with advanced ovarian carcinoma and bad performance status were subjected to daily cyclophosphamide（CTX） after failure of 1st line chemotherapy which included paclitaxel and carboplatin.Evaluation of the cases during treatment as regard treatment side effects and progression free survival.Results：Patients could tolerate low dose oral cyclophosphamide treatment without considerable side effects with improvement of performance status.The mean progression free survival was 12 months.Conclusion：Low dose oral cyclophosphamide could be considered as a palliative treatment of pretreated ovarian carcinomas with poor performance status.

Clinical application of intraperitoneal chemotherapy before surgery for ovarian cancer and its evaluation

Objective： To investigate the clinical efficacy of intraperitoneal chemotherapy before surgery for ovarian cancer. Methods： 60 patients with stages Ⅱ-Ⅳ of ovarian cancer were treated with intraperitoneal chemotherapy of CAP or TP regimen followed by a surgery treatment and another chemotherapy for 6 cycles. And then the efficiency of the therapy was evaluated by analyzing the changes of ascites, the serum CA-125 and CA-19-9 levels and the findings in the operation, and investigating the recurrence of cancer and the survival. Results： After 1-3 cycles of intraperitoneal chemotherapy, serum levels of CA-125 and CA-19-9 and carcinous ascites significantly reduced in all patients, ascites reduce was over 50% in 98.3% cases; all cases were successfully treated with cytoreduction and it was found during the operation that bulky tumor was reduced and looser so as to be easily isolated and removed; PFS of the patients was prolonged, while the toxicity and side-effects were not so serious as beyond the patient toleration. Conclusion： Intraperitoneal chemotherapy before surgery for ovarian cancer has an active efficacy in clinic, being able to improve conditions of surgery and increase the opportunity of maximal cytoreduction, and prolong survival of the patients, and should be a good selection for the treatment of advanced ovarian cancer.

Clinical significance of CA125 regression in chemotherapy of advanced ovarian cancer

Objective:The aim of this study was to compare the serum CA125 regression in advanced ovarian carcinoma patients treated with paclitaxel/platinum (TP) and platinum/epirubicin/ifosfamide (PAC) during early chemotherapy.The relationship between survival and CA125 regression during first line chemotherapy was evaluated.Methods:This retrospective investigation assessed 122 and 95 patients with stages IIc-IV ovarian carcinoma who underwent initial surgery followed by TP or PAC chemotherapy,respectively.Only epithelial ovarian cancers were included.CA125 half-life was calculated by mono-compartmental logarithmic regression.Every patient's nadir CA125 concentration was also studied.T-test was used in comparing CA125 half-life and nadir CA125 between two groups.Survival analyses for progression-free survival (PFS) and overall survival (OS) used univariate (Kaplan-Meier) and multivariate (Cox) models for all of the patients.Results:There was not significant difference in CA125 half-life and nadir CA125 concentration between two groups (P > 0.05).CA125 half-life and nadir CA125 concentration had a univariate prognostic value for PFS and OS (P < 0.0001) in all of the patients.However pre-chemotherapy CA125 and different chemotherapy agents were not prognostic factors for PFS and for OS (P > 0.05,for each).In Cox models,CA125 half-life (P=0.0006),residual tumour (P < 0.0001),and nadir concentration (P=0.0032) were significant prognostic factors for disease free survival (DFS).For OS,CA125 half-life (P=0.0013),residual tumor (P < 0.0001),and nadir concentration (P=0.0118) were also the significant prognostic factors.Conclusion:There isn't significant difference in serum CA125 regression between patients who are treated with PAC or PT during early chemotherapy.CA125 half-life and nadir CA125 concentration are independent prognostic factor in advanced ovarian cancer.